Authors


Janet Lowenbach

Latest:

Outsourcing Outlook: Will CROs find opportunity in a Reinvigorated European R&D Sector?

by Jim Miller and Janet Lowenbach, PharmSource Information Services The EU must harness market forces that reward innovation and competitiveness to combat its current R&D drain.


Jeffrey W. Hall

Latest:

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 2, Implementation Strategies

by S. Alison Arnold, Linda M. Harvey, and Brian McNeil, Strathclyde Fermentation Centre (Scotland), and Jeffrey W. Hall, FOSS NIRSystems Timely process information is required to make effective fermentation decisions, but those data are rarely available. NIR spectroscopy can allow you ? by incorporating rapid, nondestructive, multiconstituent analyses of fermentation broth directly into fermentation control strategies ? to make those decisions. This article will help you make that improvement by outlining the analysis strategies.


Brian McNeil

Latest:

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 2, Implementation Strategies

by S. Alison Arnold, Linda M. Harvey, and Brian McNeil, Strathclyde Fermentation Centre (Scotland), and Jeffrey W. Hall, FOSS NIRSystems Timely process information is required to make effective fermentation decisions, but those data are rarely available. NIR spectroscopy can allow you ? by incorporating rapid, nondestructive, multiconstituent analyses of fermentation broth directly into fermentation control strategies ? to make those decisions. This article will help you make that improvement by outlining the analysis strategies.


Masoud Hosseini

Latest:

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light

by Mary Sawyer, Masoud Hosseini, Carrie Schore, and Bennie I. Osburn from School of Veterinary Medicine, University of California, Davis, department of veterinary pathology, microbiology and immunology; Joseph Vu, Baxter biosciences division; Krystyna Trzepla-Nabaglo, Celilia Pina, and Manuel Lagunas-Solar from the laser unit, Crocker Nuclear Laboratory, University of California, Davis; and Wayne Smith, department of population health and reproduction at the University of California, Davis New evidence suggests the West Nile virus can be transmitted during blood transfusion from an asymptomatic donor. However, it is now possible to use pulsed ultraviolet laser light to inactivate viruses such as West Nile at large production scales. These experimental data show that using laser light on virus-treated media can render biological products free of contaminating viruses without compromising the biological activity essential to cell cultures.


Mary Sawyer

Latest:

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light

by Mary Sawyer, Masoud Hosseini, Carrie Schore, and Bennie I. Osburn from School of Veterinary Medicine, University of California, Davis, department of veterinary pathology, microbiology and immunology; Joseph Vu, Baxter biosciences division; Krystyna Trzepla-Nabaglo, Celilia Pina, and Manuel Lagunas-Solar from the laser unit, Crocker Nuclear Laboratory, University of California, Davis; and Wayne Smith, department of population health and reproduction at the University of California, Davis New evidence suggests the West Nile virus can be transmitted during blood transfusion from an asymptomatic donor. However, it is now possible to use pulsed ultraviolet laser light to inactivate viruses such as West Nile at large production scales. These experimental data show that using laser light on virus-treated media can render biological products free of contaminating viruses without compromising the biological activity essential to cell cultures.


Frank Bing

Latest:

Evaluation of Extractables from Product-Contact Surfaces

by the Biopharmaceutical Process Extractables Core Team, including Don Miller, Bayer; Bob Seely, Amgen; John Bennan, ComplianceNet, Inc.; Frank Bing, Abbott Laboratories; Heather Boone, Genentech; Jim Fernandez, Fernandez and Associates; and Harold van Deinse, Baxter Healthcare Corporation Potential interactions between a drug product and its packaging or container closure have always been important considerations for parenteral manufacturers. Now ? at a time of increased regulatory interest in extractables, lower limits of detection, and more biopharmaceuticals reaching commercial stage ? the consequences of not evaluating the extractables in your process stream can be significant. Participants from more than 15 biopharmaceutical companies and data collected for more than 25 years were used to develop the parameters of this article.


Bennie I. Osburn

Latest:

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light

by Mary Sawyer, Masoud Hosseini, Carrie Schore, and Bennie I. Osburn from School of Veterinary Medicine, University of California, Davis, department of veterinary pathology, microbiology and immunology; Joseph Vu, Baxter biosciences division; Krystyna Trzepla-Nabaglo, Celilia Pina, and Manuel Lagunas-Solar from the laser unit, Crocker Nuclear Laboratory, University of California, Davis; and Wayne Smith, department of population health and reproduction at the University of California, Davis New evidence suggests the West Nile virus can be transmitted during blood transfusion from an asymptomatic donor. However, it is now possible to use pulsed ultraviolet laser light to inactivate viruses such as West Nile at large production scales. These experimental data show that using laser light on virus-treated media can render biological products free of contaminating viruses without compromising the biological activity essential to cell cultures.


Wayne Smith

Latest:

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light

by Mary Sawyer, Masoud Hosseini, Carrie Schore, and Bennie I. Osburn from School of Veterinary Medicine, University of California, Davis, department of veterinary pathology, microbiology and immunology; Joseph Vu, Baxter biosciences division; Krystyna Trzepla-Nabaglo, Celilia Pina, and Manuel Lagunas-Solar from the laser unit, Crocker Nuclear Laboratory, University of California, Davis; and Wayne Smith, department of population health and reproduction at the University of California, Davis New evidence suggests the West Nile virus can be transmitted during blood transfusion from an asymptomatic donor. However, it is now possible to use pulsed ultraviolet laser light to inactivate viruses such as West Nile at large production scales. These experimental data show that using laser light on virus-treated media can render biological products free of contaminating viruses without compromising the biological activity essential to cell cultures.


Harold van Deinse

Latest:

Evaluation of Extractables from Product-Contact Surfaces

by the Biopharmaceutical Process Extractables Core Team, including Don Miller, Bayer; Bob Seely, Amgen; John Bennan, ComplianceNet, Inc.; Frank Bing, Abbott Laboratories; Heather Boone, Genentech; Jim Fernandez, Fernandez and Associates; and Harold van Deinse, Baxter Healthcare Corporation Potential interactions between a drug product and its packaging or container closure have always been important considerations for parenteral manufacturers. Now ? at a time of increased regulatory interest in extractables, lower limits of detection, and more biopharmaceuticals reaching commercial stage ? the consequences of not evaluating the extractables in your process stream can be significant. Participants from more than 15 biopharmaceutical companies and data collected for more than 25 years were used to develop the parameters of this article.


Carrie Schore

Latest:

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light

by Mary Sawyer, Masoud Hosseini, Carrie Schore, and Bennie I. Osburn from School of Veterinary Medicine, University of California, Davis, department of veterinary pathology, microbiology and immunology; Joseph Vu, Baxter biosciences division; Krystyna Trzepla-Nabaglo, Celilia Pina, and Manuel Lagunas-Solar from the laser unit, Crocker Nuclear Laboratory, University of California, Davis; and Wayne Smith, department of population health and reproduction at the University of California, Davis New evidence suggests the West Nile virus can be transmitted during blood transfusion from an asymptomatic donor. However, it is now possible to use pulsed ultraviolet laser light to inactivate viruses such as West Nile at large production scales. These experimental data show that using laser light on virus-treated media can render biological products free of contaminating viruses without compromising the biological activity essential to cell cultures.


Don Miller

Latest:

Evaluation of Extractables from Product-Contact Surfaces

by the Biopharmaceutical Process Extractables Core Team, including Don Miller, Bayer; Bob Seely, Amgen; John Bennan, ComplianceNet, Inc.; Frank Bing, Abbott Laboratories; Heather Boone, Genentech; Jim Fernandez, Fernandez and Associates; and Harold van Deinse, Baxter Healthcare Corporation Potential interactions between a drug product and its packaging or container closure have always been important considerations for parenteral manufacturers. Now ? at a time of increased regulatory interest in extractables, lower limits of detection, and more biopharmaceuticals reaching commercial stage ? the consequences of not evaluating the extractables in your process stream can be significant. Participants from more than 15 biopharmaceutical companies and data collected for more than 25 years were used to develop the parameters of this article.



Celilia Pina

Latest:

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light

by Mary Sawyer, Masoud Hosseini, Carrie Schore, and Bennie I. Osburn from School of Veterinary Medicine, University of California, Davis, department of veterinary pathology, microbiology and immunology; Joseph Vu, Baxter biosciences division; Krystyna Trzepla-Nabaglo, Celilia Pina, and Manuel Lagunas-Solar from the laser unit, Crocker Nuclear Laboratory, University of California, Davis; and Wayne Smith, department of population health and reproduction at the University of California, Davis New evidence suggests the West Nile virus can be transmitted during blood transfusion from an asymptomatic donor. However, it is now possible to use pulsed ultraviolet laser light to inactivate viruses such as West Nile at large production scales. These experimental data show that using laser light on virus-treated media can render biological products free of contaminating viruses without compromising the biological activity essential to cell cultures.


Heather Boone

Latest:

Evaluation of Extractables from Product-Contact Surfaces

by the Biopharmaceutical Process Extractables Core Team, including Don Miller, Bayer; Bob Seely, Amgen; John Bennan, ComplianceNet, Inc.; Frank Bing, Abbott Laboratories; Heather Boone, Genentech; Jim Fernandez, Fernandez and Associates; and Harold van Deinse, Baxter Healthcare Corporation Potential interactions between a drug product and its packaging or container closure have always been important considerations for parenteral manufacturers. Now ? at a time of increased regulatory interest in extractables, lower limits of detection, and more biopharmaceuticals reaching commercial stage ? the consequences of not evaluating the extractables in your process stream can be significant. Participants from more than 15 biopharmaceutical companies and data collected for more than 25 years were used to develop the parameters of this article.


Jim Fernandez

Latest:

Evaluation of Extractables from Product-Contact Surfaces

by the Biopharmaceutical Process Extractables Core Team, including Don Miller, Bayer; Bob Seely, Amgen; John Bennan, ComplianceNet, Inc.; Frank Bing, Abbott Laboratories; Heather Boone, Genentech; Jim Fernandez, Fernandez and Associates; and Harold van Deinse, Baxter Healthcare Corporation Potential interactions between a drug product and its packaging or container closure have always been important considerations for parenteral manufacturers. Now ? at a time of increased regulatory interest in extractables, lower limits of detection, and more biopharmaceuticals reaching commercial stage ? the consequences of not evaluating the extractables in your process stream can be significant. Participants from more than 15 biopharmaceutical companies and data collected for more than 25 years were used to develop the parameters of this article.


Manuel Lagunas-Solar

Latest:

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light

by Mary Sawyer, Masoud Hosseini, Carrie Schore, and Bennie I. Osburn from School of Veterinary Medicine, University of California, Davis, department of veterinary pathology, microbiology and immunology; Joseph Vu, Baxter biosciences division; Krystyna Trzepla-Nabaglo, Celilia Pina, and Manuel Lagunas-Solar from the laser unit, Crocker Nuclear Laboratory, University of California, Davis; and Wayne Smith, department of population health and reproduction at the University of California, Davis New evidence suggests the West Nile virus can be transmitted during blood transfusion from an asymptomatic donor. However, it is now possible to use pulsed ultraviolet laser light to inactivate viruses such as West Nile at large production scales. These experimental data show that using laser light on virus-treated media can render biological products free of contaminating viruses without compromising the biological activity essential to cell cultures.


Joseph Vu

Latest:

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light

by Mary Sawyer, Masoud Hosseini, Carrie Schore, and Bennie I. Osburn from School of Veterinary Medicine, University of California, Davis, department of veterinary pathology, microbiology and immunology; Joseph Vu, Baxter biosciences division; Krystyna Trzepla-Nabaglo, Celilia Pina, and Manuel Lagunas-Solar from the laser unit, Crocker Nuclear Laboratory, University of California, Davis; and Wayne Smith, department of population health and reproduction at the University of California, Davis New evidence suggests the West Nile virus can be transmitted during blood transfusion from an asymptomatic donor. However, it is now possible to use pulsed ultraviolet laser light to inactivate viruses such as West Nile at large production scales. These experimental data show that using laser light on virus-treated media can render biological products free of contaminating viruses without compromising the biological activity essential to cell cultures.


Krystyna Trzepla-Nabaglo

Latest:

Inactivating Adventitious Viruses While Preserving Biological Activity: Treating Fetal Bovine Serum with Pulsed Ultraviolet Light

by Mary Sawyer, Masoud Hosseini, Carrie Schore, and Bennie I. Osburn from School of Veterinary Medicine, University of California, Davis, department of veterinary pathology, microbiology and immunology; Joseph Vu, Baxter biosciences division; Krystyna Trzepla-Nabaglo, Celilia Pina, and Manuel Lagunas-Solar from the laser unit, Crocker Nuclear Laboratory, University of California, Davis; and Wayne Smith, department of population health and reproduction at the University of California, Davis New evidence suggests the West Nile virus can be transmitted during blood transfusion from an asymptomatic donor. However, it is now possible to use pulsed ultraviolet laser light to inactivate viruses such as West Nile at large production scales. These experimental data show that using laser light on virus-treated media can render biological products free of contaminating viruses without compromising the biological activity essential to cell cultures.


John Bennan

Latest:

Evaluation of Extractables from Product-Contact Surfaces

by the Biopharmaceutical Process Extractables Core Team, including Don Miller, Bayer; Bob Seely, Amgen; John Bennan, ComplianceNet, Inc.; Frank Bing, Abbott Laboratories; Heather Boone, Genentech; Jim Fernandez, Fernandez and Associates; and Harold van Deinse, Baxter Healthcare Corporation Potential interactions between a drug product and its packaging or container closure have always been important considerations for parenteral manufacturers. Now ? at a time of increased regulatory interest in extractables, lower limits of detection, and more biopharmaceuticals reaching commercial stage ? the consequences of not evaluating the extractables in your process stream can be significant. Participants from more than 15 biopharmaceutical companies and data collected for more than 25 years were used to develop the parameters of this article.


Gordon Kelley

Latest:

Biotech World: India Blossoms

by Gordon Kelley, BioPharm International India's rapidly growing biotech sector is infused with optimism.


David C.A. Sharp

Latest:

Monitoring and Controlling Biocatalytic Processes

by John Woodley and Paul A. Bird, the Advanced Centre for Biochemical Engineering at University College, London, and David C.A. Sharp, Pfizer Global R&D. Increased selectivity and byproduct prevention are some of the advantages of using biocatalytic processes for manufacturing chiral products and chemical intermediates. yet no industrial processes are currently using biocatalysts with Baeyer?Villiger monooxygenases because, among other factors, available monitoring and control techniques have not been rapid enough to prevent reactant and product inhibition. However, as the authors describe, rapid monitoring and control can now be achieved using near-infrared spectroscopy that, during tests, resulted in a 30% gain in productivity.


Paul A. Bird

Latest:

Monitoring and Controlling Biocatalytic Processes

by John Woodley and Paul A. Bird, the Advanced Centre for Biochemical Engineering at University College, London, and David C.A. Sharp, Pfizer Global R&D. Increased selectivity and byproduct prevention are some of the advantages of using biocatalytic processes for manufacturing chiral products and chemical intermediates. yet no industrial processes are currently using biocatalysts with Baeyer?Villiger monooxygenases because, among other factors, available monitoring and control techniques have not been rapid enough to prevent reactant and product inhibition. However, as the authors describe, rapid monitoring and control can now be achieved using near-infrared spectroscopy that, during tests, resulted in a 30% gain in productivity.


John Woodley

Latest:

Monitoring and Controlling Biocatalytic Processes

by John Woodley and Paul A. Bird, the Advanced Centre for Biochemical Engineering at University College, London, and David C.A. Sharp, Pfizer Global R&D. Increased selectivity and byproduct prevention are some of the advantages of using biocatalytic processes for manufacturing chiral products and chemical intermediates. yet no industrial processes are currently using biocatalysts with Baeyer?Villiger monooxygenases because, among other factors, available monitoring and control techniques have not been rapid enough to prevent reactant and product inhibition. However, as the authors describe, rapid monitoring and control can now be achieved using near-infrared spectroscopy that, during tests, resulted in a 30% gain in productivity.


Jack Dolmat

Latest:

Survival Strategies: Board Compensation Changing with the Times

by Jack Dolmat, Clark/Bardes Consulting Compensation for board members varies widely with company size, but as more is expected, compensation practices are changing too.


Ajoy Velayudhan

Latest:

Guidelines for Optimization and Scale-Up in Preparative Chromatography

Anurag Rathore, Pharmacia Corporation and Ajoy Velayudhan Optimizing your purification and separation process when your complex biological feedstock is ready for scale-up can be daunting. Your design process can be streamlined, simplified, and made cost efficient if you supplement your empirical approach with the theoretical and experimental tools presented in this article.


Mark Tuomenoska

Latest:

Outsourcing Outlook: Using Virtual Private Networks to Gain Competitive Advantage

by Mark Tuomenoska, OpenReach, Inc. and Jim Miller, Bio/Pharmaceutical Outsourcing Report Outsourcing can be a booster rocket in the race to patent and market innovative products.


Leaford Blevins

Latest:

Reducing Costs by Facility Design

by Leaford Blevins and Tom Gerbo, HDR Facility design can affect the bottom line in biopharmaceutical manufacturing. The authors offer insights about what to look for and what to consider in facility design ? whether you're retrofitting an existing facility or building from the ground up.


Tom Gerbo

Latest:

Reducing Costs by Facility Design

by Leaford Blevins and Tom Gerbo, HDR Facility design can affect the bottom line in biopharmaceutical manufacturing. The authors offer insights about what to look for and what to consider in facility design ? whether you're retrofitting an existing facility or building from the ground up.


Tim N. Warner

Latest:

Rethinking the Economics of Chromatography: New Technologies and Hidden Costs

by Tim N. Warner and Sam Nuchumson, Pall Life Sciences If the hidden expenses associated with laboratory purchases ? labor, cleaning, buffers, validation, time delays ? are identified, reduced processing costs, higher throughput, and accelerated time-to-market are possible. This comparison between resin and membrane chromatography helps shed light on some hidden costs.


Sam Nuchumson

Latest:

Rethinking the Economics of Chromatography: New Technologies and Hidden Costs

by Tim N. Warner and Sam Nuchumson, Pall Life Sciences If the hidden expenses associated with laboratory purchases ? labor, cleaning, buffers, validation, time delays ? are identified, reduced processing costs, higher throughput, and accelerated time-to-market are possible. This comparison between resin and membrane chromatography helps shed light on some hidden costs.

© 2025 MJH Life Sciences

All rights reserved.